This post was originally published on this site Evomela, an injectable formulation of melphalan, is now available in China as a high-dose conditioning therapy for people with multiple myeloma who will undergo a stem cell transplant, CASI Pharmaceuticals, its maker, announced. The product is also approved as a palliative treatment for patients who cannot take oral medicines.…
Conditions
Conditions
Immix Cleared to Expand Phase 1/2a Trial of IMX-110 to US Sites
This post was originally published on this site A Phase 1/2a trial testing the advanced solid tumor treatment candidate IMX-110 in Australia has been cleared by the U.S. Food and Drug Administration to enroll participants in the United States. Immix is now selecting the medical centers that will participate in the trial. Australia is the…
Caregiving Tasks Fluctuate between Urgent and Necessary
This post was originally published on this site One of the greatest privileges of my life was to care for my mother, who had Alzheimer’s disease. However, I was constantly fighting an internal battle. A feeling of inadequacy always bubbled beneath the surface. Many caregivers fight similar battles. This is why I wrote the following,…
Middle-Age Adults With High Blood Pressure at Greater Risk of Dementia, Study Suggests
This post was originally published on this site People with high blood pressure, or hypertension, during midlife are at a greater risk of developing dementia, irrespective of their blood pressure later on, a long-term follow-up study suggests. The study, “Association of Midlife to Late-Life Blood Pressure Patterns With Incident Dementia,” was published in the Journal…
Phase 2 Trial of NeuVax Vaccine for HER2-positive DCIS Fully Enrolled, Sellas Announces
This post was originally published on this site The Phase 2 trial evaluating Sellas Life Sciences‘ cancer vaccine NeuVax as a treatment for women with early stage HER2-positive ductal carcinoma in situ (DCIS), a non-invasive breast cancer, has completed patient enrollment. The vaccine is made of Sellas’ nelipepimut-S, the active ingredient that educates the immune system…
Sarcoidosis Educational Event Set for Saturday at University of Cincinnati
This post was originally published on this site An educational conference for people with sarcoidosis and those close to them will be held at the University of Cincinnati this Saturday, featuring doctors with expertise in this disease, presentations, and a question-and-answer session. The Aug. 24 event at the Ohio university’s Kresge Auditorium runs from 10:00 a.m. to 4:00…
Risk of Multiple Myeloma in People with MGUS Can Rise Over Time, Study Finds
This post was originally published on this site People with monoclonal gammopathy of undetermined significance (MGUS) placed at low- or intermediate-risk of progression to multiple myeloma can develop that cancer within five years, a study of blood serum immune markers reports. This finding warrants annual blood testing for these people, researchers wrote in the study…
Survival Benefits of High-Volume Ovarian Cancer Surgery Centers Come at Accessibility Cost, Study Says
This post was originally published on this site Hospitals that perform many ovarian cancer surgeries tend to have better treatment outcomes in terms of mortality, a study suggests. But restricting this surgery to only high-volume hospitals would greatly limit treatment availability while only meagerly increasing survival rates, the researchers say. The study, published in the…
Phase 1 Trial Enrolling Advanced, Castration-resistent Patients to Test Triple Immunotherapy Combo
This post was originally published on this site A Phase 1 trial is enrolling people with metastatic castration-resistant prostate cancer (mCRPC) to test Inovio Pharmaceutical‘s immunotherapy INO-5151 in combination with two other immunotherapies — Celldex’s CDX-301 and Bristol-Myers Squibb’s Opdivo (nivolumab). The PORTER study (NCT03835533) will include 45 patients who were previously treated with second-generation androgen receptor inhibitors…
test
This post was originally published on this site The post test appeared first on Diabetes News Journal. The post test appeared first on BioNewsFeeds.
INmune Bio Shares Early Results of Phase 1 Trial of INB03 for Advanced Cancer Treatment
This post was originally published on this site INmune Bio’s therapy candidate INB03 is well-tolerated and has shown signs of activity in patients with advanced cancers, according to preliminary findings from a Phase 1 clinical trial. The early results were revealed recently at the Cambridge Healthtech Institute’s 7th Annual Immuno-Oncology Summit, in the presentation, “Targeting Soluble…
Clinical Trials in China Will Test Abexinostat for DLBCL, Follicular Lymphoma
This post was originally published on this site Xynomic Pharma is launching two pivotal clinical trials in China to test its investigational HDAC inhibitor, abexinostat, as a third-line therapy for two types of non-Hodgkin’s lymphoma: diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, The announcement came after China’s National Medical Products Administration (NMPA) approved the trials, which will be…